九安醫療(002432.SZ):公司試劑盒類產品,目前已廣泛覆蓋亞馬遜、CVS和沃爾瑪等線上及線下零售渠道
格隆匯5月22日丨九安醫療(002432.SZ)在互動平臺表示,公司試劑盒類產品,目前已廣泛覆蓋亞馬遜、CVS和沃爾瑪等線上及線下零售渠道,產品銷售情況與上呼吸道疾病發病率直接相關,iHealth試劑盒產品銷量長期位居該品類的Best Seller。公司會積極關注市場動態和美國政府的相關政策,努力拓展業務渠道,爭取在滿足C端和B端需求的基礎上,如有政府端採購需求,公司會力爭抓住機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.